Tag: electronic kidney fibrosis treatment market growth

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Kidney Fibrosis Treatment Market?

The market size for kidney fibrosis treatment has shown substantial growth recently. It is projected to expand from $5.62 billion in 2024 to $6.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.8%. This historical expansion is largely due to several factors, including escalating investments in research and development for therapies targeting fibrosis, a rise in government funding aimed at kidney disease management initiatives, enhanced patient understanding of kidney transplantation and available fibrosis treatment choices, improvements in healthcare infrastructure, and the growing incidence of aging populations.

The kidney fibrosis treatment market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $8.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.9%. This anticipated growth during the forecast period is primarily driven by the escalating occurrence of chronic kidney diseases, a heightened need for sophisticated treatments in managing renal fibrosis, increased recognition of the importance of detecting kidney fibrosis early, wider acceptance of personalized medicine approaches for kidney conditions, and the growing rates of diabetes and hypertension. Key trends expected over this period encompass technological progress in diagnostic and early detection methods, innovations in gene therapy, the incorporation of technology into telemedicine and remote monitoring, developments in stem cell therapies, and improvements in drug delivery systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Drivers Are Supporting Growth Of The Kidney Fibrosis Treatment Market?

The market for kidney fibrosis treatment is anticipated to expand due to the growing occurrence of chronic kidney diseases. Chronic Kidney Disease (CKD) signifies a progressive decline in kidney function over time, frequently caused by ailments like diabetes or hypertension, leading to the buildup of toxins within the body. A significant contributor to the increasing incidence of CKD is the escalating prevalence of diabetes, which harms renal blood vessels and compromises their filtration capabilities. Kidney fibrosis treatment aids patients with Chronic Kidney Disease (CKD) by addressing the scarring of renal tissue, mitigating inflammation, and decelerating the advance of kidney damage, thereby preserving kidney function. For example, data from May 2024, provided by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that an estimated 14% of U.S. adults, equating to about 35.5 million people, are thought to have chronic kidney diseases. Consequently, the expanding occurrence of chronic kidney diseases is fueling the expansion of the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Classified Into Different Segments?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Industry Leaders Are Driving Innovation Across The Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Regional Markets Are Contributing Most To The Kidney Fibrosis Treatment Industry Expansion?

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Kidney Fibrosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2025, By The Business Research Company

Kidney Transplant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

Artificial Kidney Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-kidney-global-market-report

Rare Kidney Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Kidney Fibrosis Treatment Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for treatment of kidney fibrosis has seen substantial growth in the past few years. The prediction is that it will increase from $5.62 billion in 2024 to $6.06 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%. The historical growth is largely due to increased investment in research and development for therapies focused on fibrosis, enhanced government support for initiatives managing kidney diseases, heightened patient consciousness about opportunities for kidney transplantation and fibrosis treatment, an expansion of health care facilities, and the growing number of elderly individuals.

Growth predictions anticipate significant enlargement for the kidney fibrosis treatment market in the coming few years. The market is projected to escalate to $8.21 billion by 2029, with a compound annual growth rate of 7.9%. Several contributing factors driving the growth during the forecast period include an escalating number of chronic kidney disease cases, enhanced demand for state-of-the-art renal fibrosis therapies, and a growing recognition of early kidney fibrosis detection. Other influences include the heightening attention to personalized medicine in treating kidney disease, and the increasing occurrence of diabetes and hypertension. Major trends for the forecast period incorporate advancements in technology for early detection and diagnostic tools, progression in gene therapy initiatives, the incorporation of technology in telemedicine and remote oversight, advancements in stem cell therapies, along with improvements in drug delivery systems.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What External and Internal Drivers Are Contributing to the Growth of theKidney Fibrosis Treatment Market?

The escalation in the occurrence of chronic kidney diseases is projected to spur the expansion of the kidney fibrosis treatment market in the future. Chronic kidney disease (CKD) characterizes a steady deterioration of kidney function over a span of time, often as a result of conditions such as diabetes or hypertension. This eventual deterioration leads to the build-up of waste products within the body. The growth in the prevalence of CKD is mainly attributable to the increasing instances of diabetes, which harms the kidney blood vessels and hinders their ability to filter. Kidney fibrosis treatment aids CKD patients by focusing on the scarring of the kidney tissue, lessening inflammation, and decelerating kidney damage, which all aid in the conservation of kidney function. To illustrate, in May 2024, the Centers for Disease Control and Prevention (CDC), a public health agency in the US, estimated that about 14% of adults in the U.S., or around 35.5 million people, are thought to be affected with chronic kidney diseases. Hence, the rising occurrence of chronic kidney diseases is stimulating the advancement of the kidney fibrosis treatment market.

What Segment Types Define the Kidney Fibrosis Treatment Market Structure?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

View the full report here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

What Is the Definition of the Kidney Fibrosis Treatment Market?

Kidney fibrosis treatment refers to therapeutic strategies aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive accumulation of extracellular matrix proteins such as collagen, resulting to scarring and functional decline of kidney tissue, commonly associated with chronic kidney disease (CKD).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24271

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Kidney Fibrosis Treatment Market?

The market for kidney fibrosis treatment has experienced significant growth in the past few years. Its total value is projected to rise from $6.93 billion in 2024 to $7.58 billion in 2025, marking an annual compound growth rate (CAGR) of 9.4%. This historical growth is due, in part, to increased investment in R&D for fibrosis targeting therapies, government-funded initiatives focused on kidney disease management, a rise in patient awareness regarding kidney transplant and fibrosis treatment options, improved healthcare infrastructure, and an increase in the aging population.

What Growth Rate Is Forecasted for the Kidney Fibrosis Treatment Market by 2029?

Forecasted to observe a rapid expansion in the coming years, the kidney fibrosis treatment market size is predicted to reach $10.78 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%. This growth during the forecast period is linked to a rising prevalence of chronic kidney illness, an escalating demand for cutting-edge therapies to manage renal fibrosis, increasing awareness of kidney fibrosis detection at early stages, the growing implementation of personalized medicine in treating kidney disease, as well as the escalating frequency of both diabetes and hypertension. Prominent trends expected in the forecast period encompass technological enhancements in early detection and diagnostic tools, advancements in gene therapy, the integration of technology in telemedicine and remote monitoring, improvements in stem cell therapies, and progress in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Key Companies Are Shaping the Future of the Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

Which Factors Are Driving Demand in the Kidney Fibrosis Treatment Industry?

The escalating occurrence of chronic kidney diseases is set to drive the expansion of the kidney fibrosis treatment market in the future. The gradual dysfunction of the kidney over time, commonly referred to as chronic kidney disease (CKD), often results from issues such as diabetes or hypertension, leading to accumulation of waste products in the body. The surge in the prevalence of CKD is primarily due to increasing rates of diabetes, which can damage blood vessels in the kidney and compromise its filtration capacity. By targeting tissue scarring in the kidney, reducing inflammation, and decelerating kidney damage progression, kidney fibrosis treatment proves beneficial for CKD patients in conserving kidney function. For instance, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, attested in May 2024 that an estimated 14% of U.S. adults, translating to about 35.5 million individuals, are purportedly suffering from chronic kidney diseases. Hence, the growth rate of the kidney fibrosis treatment market is being propelled by the rising prevalence of chronic kidney diseases. The expansion of the kidney fibrosis treatment market is also being spurred by increasing clinical trial activities in pursuit of innovative and personalized therapies. Clinical trials are human research studies aimed at estimating the safety, effectiveness and possible adverse effects of medical treatments or interventions. The drive for personalized and ground-breaking treatments that calls for in-depth safety and efficiency testing results in ever-increasing clinical trials. The presence of a defined target area for novel anti-fibrotic therapies testing by kidney fibrosis treatment contributes to these clinical trials, allowing researchers to assess the ability of new drugs to decelerate or reverse kidney damage. In an example, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported in November 2023 that the annual recruitment to industry clinical trials in the UK showed a 15% rise, moving from 36,722 participants in 2021-22 to 42,088 in 2022-23. Hence, the escalating number of clinical trials fosters the growth of the kidney fibrosis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

How Is the Kidney Fibrosis Treatment Market Segmented by Several Divisions?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Regions Are Driving Growth in the Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

This Report Delivers Insight On:

1. How big is the kidney fibrosis treatment market, and how is it changing globally?

2. Who are the major companies in the kidney fibrosis treatment market, and how are they performing?

3. What are the key opportunities and risks in the kidney fibrosis treatment market right now?

4. Which products or customer segments are growing the most in the kidney fibrosis treatment market?

5. What factors are helping or slowing down the growth of the kidney fibrosis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model